Antibody treatments clear amyloid protein from patients’ brains, slowing the progression of their disease but potentially inducing deadly swelling.
Read this story <a href="https://www.wired.com/story/alzheimers-drugs-benefits-risks-lecanemab-donanemab/">here</a>. 
 Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices">podcastchoices.com/adchoices</a>

Antibody treatments clear amyloid protein from patients’ brains, slowing the progression of their disease but potentially inducing deadly swelling. Read this story here. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Antibody treatments clear amyloid protein from patients’ brains, slowing the progression of their disease but potentially inducing deadly swelling.
Read this story <a href="https://www.wired.com/story/alzheimers-drugs-benefits-risks-lecanemab-donanemab/" rel="noopener noreferrer">here</a>. 
 Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices" rel="noopener noreferrer">podcastchoices.com/adchoices</a>

New Alzheimer’s Drugs Offer Subtle Benefits—With Real Risks

Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.

Share New Alzheimer’s Drugs Offer Subtle Benefits—With Real Risks

Sign up to save your podcasts

New Alzheimer’s Drugs Offer Subtle Benefits—With Real Risks

New Alzheimer’s Drugs Offer Subtle Benefits—With Real Risks

More shows like Science, Spoken

This American Life

Freakonomics Radio

Dr Karl Podcast

What's New

Business, Spoken

Security, Spoken

Citadel Dropouts: a Game of Thrones Podcast